Literature DB >> 23986400

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Stefani Spranger1, Robbert M Spaapen, Yuanyuan Zha, Jason Williams, Yuru Meng, Thanh T Ha, Thomas F Gajewski.   

Abstract

Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8(+) T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3(+) regulatory T cells (T(regs)), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8(+) T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T(regs), in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-γ and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23986400      PMCID: PMC4136707          DOI: 10.1126/scitranslmed.3006504

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  47 in total

1.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

Review 2.  T cell clonal anergy.

Authors:  R H Schwartz
Journal:  Curr Opin Immunol       Date:  1997-06       Impact factor: 7.486

3.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

Authors:  L Chen; S Ashe; W A Brady; I Hellström; K E Hellström; J A Ledbetter; P McGowan; P S Linsley
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

8.  PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Authors:  Christian Blank; Ian Brown; Amy C Peterson; Mike Spiotto; Yoshiko Iwai; Tasuku Honjo; Thomas F Gajewski
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

Authors:  S E Townsend; J P Allison
Journal:  Science       Date:  1993-01-15       Impact factor: 47.728

10.  12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

Authors:  Jane L Messina; David A Fenstermacher; Steven Eschrich; Xiaotao Qu; Anders E Berglund; Mark C Lloyd; Michael J Schell; Vernon K Sondak; Jeffrey S Weber; James J Mulé
Journal:  Sci Rep       Date:  2012-10-24       Impact factor: 4.379

View more
  668 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 3.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

Review 4.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

5.  Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Authors:  Andrew J Rech; Robert H Vonderheide
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397

6.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

7.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

8.  PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.

Authors:  Melanie Boxberg; Katja Steiger; Ulrich Lenze; Hans Rechl; Rüdiger von Eisenhart-Rothe; Klaus Wörtler; Wilko Weichert; Rupert Langer; Katja Specht
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

9.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Authors:  Xiaofang Xing; Jianping Guo; Guangyu Ding; Bo Li; Bin Dong; Qin Feng; Shen Li; Jian Zhang; Xiaomin Ying; Xiaojing Cheng; Ting Guo; Hong Du; Ying Hu; Tao Zhou; Xiaohong Wang; Lin Li; Qingda Li; Meng Xie; Liting Li; Xiangyu Gao; Fei Shan; Ziyu Li; Xianzi Wen; Jiping Wang; Jiafu Ji
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

10.  Adoptive transfer of IFN-γ-induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway.

Authors:  Fan Yang; Yang Li; Weilong Zou; Yanan Xu; Hao Wang; Wei Wang; Yong Zhao
Journal:  Inflamm Res       Date:  2019-05-04       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.